Molecular Partners AG Overview
Valuation check: MOLN's P/E ratio is -2.04, below the Healthcare sector average of 27.22.
Get informed when a big investor buys or sells
+ Follow-2.04
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, MOLN shows a P/E ratio of -2.04. That is below the Healthcare sector average of 27.22. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 27.22. Molecular Partners AG is at -2.04, which is lower that average. That is roughly 107.5% below the sector mean. Use the comparison chart on this page to see how MOLN stacks up against individual peers as well.
Investors watch MOLN's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Molecular Partners AG's latest reading is -2.04. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Molecular Partners AG's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -2.04) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 27.22, while MOLN is at -2.04. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
